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Can we know in advance whether models will get it right?
Validation of model predictions against real-world data 
is worthwhile,1 yet few have been able, or are brave 
enough, to actually do it. Thankfully, in The Lancet Global 
Health, Jeﬀ rey Eaton and colleagues2 have stepped up to 
the challenge, using ten models calibrated to data from 
2002–12 to predict HIV prevalence in South Africa in 
2012 before the release of estimates from the national 
household survey done in 2012. 
Overall, the models got many of the details correct, 
such as a shift in HIV burden from younger to older age 
groups, but got the big picture wrong—predicting stable 
or declining overall prevalence, whereas prevalence 
actually increased from 16·9% to 18·8% (diﬀ erence 
1·9, 95% CI –0·1 to 3·9). Only one model predicted a 
noticeable increase in HIV prevalence towards the level 
measured in the survey, and the best estimates of only 
two of the ten models were within the 95% CIs of the 
2012 household survey data. This ﬁ nding raises the 
sobering question: if we can get model predictions so 
wrong in the data-rich setting of South Africa, where 
there are ten leading HIV epidemiological modelling 
groups focusing their attention, where can we get it 
right with conﬁ dence? 
One possible answer is to redeﬁ ne what is meant by 
getting it right. Three of the ten models included in this 
study incorporated uncertainties—credible intervals 
based on Bayesian analysis—in their results. For most 
indicators for these three models, the empirical data 
did fall within the uncertainty bounds of the models. 
If all models provide wide limits of possible epidemic 
projections based on all plausible trajectories, which 
ultimately include what does occur in future ﬁ ndings, 
then they could be regarded as right, but they would not 
be very helpful. 
It is also possible that models can correctly predict 
what would have been expected to occur, had 
unforeseen changes in underlying conditions not 
aﬀ ected the epidemic. These conditions could, for 
example, be political, ﬁ nancial, programmatic, or 
behavioural in nature. In such circumstances, the 
models project a counterfactual that can be compared 
with the actual outcome to assess the eﬀ ect of the 
changes in conditions, but in themselves might not 
be able to be validated. Despite this limitation, this 
type of epidemiological modelling is the best approach 
we have for informing decisions about changing 
conditions at the time when decisions need to be made. 
Although some conditions inevitably diﬀ er over time 
compared with the assumptions included in models, the 
dominant relevant condition to have changed in South 
Africa over the period of projections was the uptake 
of, and adherence to, eﬀ ective antiretroviral therapy 
(ART), which most model predictions were able to 
closely resemble. 
The fact that the models in this study were 
consistently wrong in their overall predictions of change 
in prevalence is itself telling. For example, all models 
assumed that ART was 90% eﬀ ective at preventing HIV 
transmission. This assumption was based on empirical 
estimates in ideal settings that might not accurately 
represent real-world retention in care and treatment 
adherence. One possible explanation for the inaccuracies 
of the models is that their assumed ART eﬀ ectiveness 
levels were too high and the real-world eﬀ ectiveness of 
ART for reducing transmission is actually substantially 
lower. This explanation is an example of how models, 
when calibrated against empirical data, can provide 
scientiﬁ c or programmatic insight. It also highlights 
again that one of the largest questions remaining for 
the HIV specialty is the amount of real-world prevention 
eﬀ ectiveness aﬀ orded by ART at various levels of viral 
suppression. 
Adjusting the models to take into account the new 
data in South Africa, potentially by decreasing the 
assumed preventive eﬀ ectiveness of ART until further 
evidence becomes available, and also calibrating the 
models against additional sources of data (eg, sex-
speciﬁ c incidence, prevalence, and mortality data) will 
further reﬁ ne the precision of the projections for future 
use and increase the conﬁ dence in model outputs for 
South Africa. The largest implication of the study by 
Eaton and colleagues2 is that future resource needs 
will probably be greater than previously expected. 
With heavily constrained budgets, this ﬁ nding 
highlights the substantial need to achieve eﬃ  ciency 
gains—both targeting programmes geographically by 
population group with the right combination of cost-
eﬀ ective interventions for the epidemic context3 and 
particularly through delivery of these services in the 
most eﬃ  cient manner. 
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In other settings with fewer available data, the 
conﬁ dence that can be placed in model outputs is 
related to the quality of the inputs. However, models are 
not designed to be authoritatively right in predictions. 
Rather, despite their limitations, they are instruments 
for assessment of the available data, often attempting 
to reconcile several sources of data together, to provide 
implications, inferences, and further insights with 
more rigorous predictions from the knowledge base 
than could be achieved otherwise through simple 
extrapolation of past trends or speculation. 
Important global and public health decisions are made 
on the basis of knowledge of the magnitude and trends 
in incidence and prevalence of infection or disease, 
which can generally only be inferred at a population level 
through the use of epidemiological models. Therefore, 
appraisal of the validity of models, particularly through 
comparisons of model predictions with data that are 
later reported, is crucial but rarely done. We commend 
Eaton and colleagues for comparing outputs from 
diﬀ erent models for the same context and undertaking 
an honest appraisal of model projections. Their study is 
a very useful exercise and we hope to see more of these 
comparison studies in the future.
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